Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts By Watertime - March 12, 2026 6 Post Content RELATED ARTICLESMORE FROM AUTHOR Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts The Vital Conference: Breckenridge 2026
